Novo Nordisk bets up to $2.6bn on Hengrui’s once-weekly oral GLP-1/GIP drug
Novo Nordisk licenses Hengrui’s once-weekly oral GLP-1/GIP candidate HRS-1596 in a deal worth up to $2.6 billion.
Pharma & Biotech
Novo Nordisk licenses Hengrui’s once-weekly oral GLP-1/GIP candidate HRS-1596 in a deal worth up to $2.6 billion.